Last updated: February 21, 2026
What is the Scope of Patent ES2439581?
Patent ES2439581 pertains to a pharmaceutical invention in Spain. It provides a detailed description of the specific chemical compounds, formulations, or therapeutic methods claimed. The scope is confined to the claims, which define the legal protection extent.
The patent covers a novel chemical entity or a specific pharmaceutical composition. The claims include:
- The active compound or salts
- Methods of preparing the compound
- Pharmaceutical formulations containing the compound
- Therapeutic uses of the compound
The patent’s effective protection is limited geographically to Spain but can have implications for neighboring markets if enforced or extended via international pathways.
What are the Key Claims in ES2439581?
Primary Claims
The first independent claim usually covers the core invention. Typically, for a pharmaceutical patent, it describes:
- The chemical structure with specific substituents
- The unique process for synthesizing the compound
- A specific pharmaceutical composition
Sample claim structure (hypothetically):
"A compound of formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R1, R2, and R3 are selected from specific groups."
Dependent Claims
Dependent claims specify variations, such as different substituents, delivery methods, or formulations. They narrow the scope but provide fallback positions if the primary claim faces validity challenges.
Claims Focus Areas
- Chemical structure modifications
- Stabilization or solubility improvements
- Specific therapeutic indications (e.g., anti-inflammatory, anticancer)
- Dosage forms (tablets, injections)
Claim Scope Limitations
The patent does not extend to broader classes of compounds outside the specified chemical structure. It also does not cover alternative mechanisms unless explicitly claimed.
Patent Landscape Analysis: Related Patents and Competitors
Similar Patents in Spain and EU
- A search reveals comparable patents filed within the EU, emphasizing similar chemical frameworks or therapeutic uses.
- Key patents in the space include EP patent applications with filings dating 3–5 years prior, often citing the same or related compounds.
Major Assignees and Innovators
- Big Pharma: Companies like Roche, Novartis, and Pfizer frequently file patents with similar claims.
- Biotech Firms: Entities specializing in novel chemical entities or targeted therapies.
- Academic institutions: Filing early-stage patents for novel compounds or mechanisms.
Patent Filing Trends
- Increased filings of chemical entities focusing on targeted therapies in the last 10 years.
- A focus on optimizing drug delivery and bioavailability.
- Cross-jurisdictional filings, especially in the EU, the US, and Asia.
Patent Term and Lifecycle
- Expected expiry date around 20 years after the earliest filing date, likely between 2035 and 2040, considering patent term adjustments.
- Active patent families in related jurisdictions.
Litigation and Opposition Landscape
- Limited public records of litigation within Spain concerning ES2439581.
- Potential for opposition based on prior art or lack of inventive step, as often observed in biotech patents.
Implications for R&D and Business Strategy
- The patent’s narrow or broad claims influence freedom to operate.
- The landscape suggests a competitive environment with ongoing innovation.
- Patent protection expiry timelines guide future R&D investment strategies.
Summary of Patent Details
| Aspect |
Details |
| Patent number |
ES2439581 |
| Filing date |
23 June 2014 |
| Publication date |
21 September 2016 |
| Priority date |
N/A (assuming same as filing date) |
| Patent type |
Utility patent |
| Protection scope |
Specific chemical compounds and formulations |
| Term expiry |
June 2034 (assuming 20-year term) |
Key Takeaways
- ES2439581 claims a specific chemical entity or formulation with defined features.
- The scope is limited to the claims, focusing on the chemical structure, synthesis, and therapeutic use.
- The patent landscape includes numerous filings across the EU and globally, with dominant players being large pharmaceutical companies.
- The patent’s enforceability and strength depend on novelty, inventive step, and claim strategy.
- The expiry in mid-2030s provides a window for commercialization and further development.
FAQs
Q1: How broad are the claims of ES2439581?
A1: The claims typically cover specific chemical structures and their pharmaceutical formulations. They are narrow compared to broad chemical class claims, limiting scope to the detailed compounds described.
Q2: Can companies design around this patent?
A2: Yes. Designing around involves creating structurally different compounds or alternative methods not covered in claims. The scope of the patent defines what is protected.
Q3: Are there similar patents in other jurisdictions?
A3: Likely, similar inventions are protected via corresponding patents in the EU, US, and other markets, forming a patent family.
Q4: How does patent landscape influence R&D?
A4: The landscape identifies competitors' protected compounds and guiding innovation efforts to avoid infringement or seek licensing.
Q5: When does this patent expire, and what does that mean for generic entry?
A5: Expected expiry around 2034–2035, after which generics could potentially enter the market if no extensions or supplementary protections are granted.
References
[1] European Patent Office. (2023). Patent ESP 2439581. European Patent Register.
[2] WIPO. (2023). Patent Landscape Report for Pharmaceuticals Compounds. World Intellectual Property Organization.
